Aims/hypothesis: Inflammation could play a part in insulin resistance. Thiazolidinediones, new antidiabetic drugs, possess anti-inflammatory effects in vitro. We investigated if acute-phase serum proteins are increased in patients with Type II (non-insulin-dependent) diabetes mellitus who had been treated with insulin and whether troglitazone has anti-inflammatory effects in vivo.
Methods: A total of 27 patients (age 63.0+/-1.7 years, HbA1c 8.8+/-0.3%, BMI 32.7+/-0.8 kg/m2, duration 15.2+/-1.4 years, insulin dose 73.3+/-7.0 U/day) participated in the study. The patients received daily either 400 mg troglitazone or placebo for 16 weeks. Blood samples were taken at baseline, at the end of therapy and after a follow-up time of 23+/-4 days.
Results: The concentrations of serum amyloid A (6.2+/-1.1 mg/l) and C-reactive protein (6.1+/-1.1 mg/l) were increased (p < 0.001) and complement protein C3 (1.69+/-0.05 g/l) was also above the reference range for healthy subjects. Placebo treatment had no effect on glucose or inflammation, whereas troglitazone reduced fasting glucose (from 10.4+/-0.6 mmol/l to 8.1+/-0.5 mmol/l, p < 0.01), HbA1c (from 8.7+/-0.3% to 7.5+/-0.3%, p < 0.01), insulin requirements (from 75+/-10 U/day to 63+/-10 U/day, p < 0.05), serum amyloid A (from 6.3+/-1.5 mg/l to 4.0+/-1.3 mg/l, p = 0.001), alpha-1-acid glycoprotein (from 906+/-51 mg/l to 729+/-52 mg/l, p = 0.001) and C3 (from 1.72+/-0.07 g/l to 1.66+/-0.06 g/l, p < 0.05) but not alpha-1-antitrypsin, ceruloplasmin, C-reactive protein or haptoglobin significantly. Concentrations of glucose and acute-phase reactants had returned to those before treatment at the follow-up visit.
Conclusion/interpretation: In Type II diabetic patients serum amyloid A and complement protein C3 are raised. Troglitazone exerts a selective reversible action on some acute-phase proteins and C3 but not on others in conjunction with the improvement in glucose metabolism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s001250051315 | DOI Listing |
Res Vet Sci
December 2024
School of Biosciences and Veterinary Medicine, University of Camerino, 62024 Matelica, MC, Italy.
Lymphoma is the most common neoplasia in the intestine of cats. According to ACVIM consensus statement, low-grade intestinal T-cell lymphoma (LGITCL) represents a monomorphic infiltration of the lamina propria or epithelium or both of cats with small, mature, neoplastic (clonal) T lymphocytes. Despite the importance as contributing factors of inheritance and environment in the pathogenesis of LGITCL, the chronic inflammatory status plays a fundamental role.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of North Dakota, Grand Forks, ND, USA.
Background: Alzheimer's disease (AD) is an age-related neurodegenerative disorder affecting nearly 50 million individuals worldwide. Besides aging, various comorbidities can increase the risk of AD, such as asthma. However, the molecular mechanism(s) underlying this asthma-associated AD exacerbation is unknown.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Catholic University of Korea, Seoul, Korea, Republic of (South).
Background: Women's elevated risk of Alzheimer's disease (AD) compared to men remains unclear, with gonadal hormones proposed as potential contributors. This study aimed to explore the association between follicle-stimulating hormone (FSH), estradiol (E2), neuropsychological AD stages, and cerebral Aβ deposition.
Methods: A total of 679 subjects were included in the study (N = 198 for cognitively normal (CN), N = 373 for mild cognitive impairment (MCI), and N = 108 for AD dementia groups).
Alzheimers Dement
December 2024
University of California Irvine, Irvine, CA, USA.
Background: Anti- Aβ monoclonal antibodies are the first FDA-approved treatments for AD that slow cognitive decline and lower Aβ plaques. Our goal is to identify the epitope specificities of antibodies in human blood that are associated with AD and NC and determine the predicted protein targets of these antibodies.
Method: 101 AD (MMSE < 27) and 98 NC (MMSE > 27) serum samples were obtained from the UCI tissue repository.
Alzheimers Dement
December 2024
UK Dementia Research Institute at Cardiff University, Cardiff, South Glamorgan, United Kingdom.
Background: Genome-wide association studies (GWAS) in Alzheimer's disease (AD) implicate complement in pathogenesis. Complement receptor 1 (CR1; CD35) is a top AD-associated GWAS hit; the long variant, CR1*2, associates with risk. The roles of CR1 in brain and how variants influence AD risk are poorly understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!